Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 5
Submit an article Journal homepage
106
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

A multicenter report on the natural history of myelodysplastic syndromes in very old patients (aged over 85 years)

Laura S. McDonaldHaematology, Tallaght University Hospital, Dublin, Ireland; Correspondence[email protected]
,
Peter McCarthyHaematology, Cork University Hospital and University College Cork, Cork, Ireland;
,
Mohammad KhanHaematology, Beaumont Hospital, Dublin, Ireland;
,
Patrick HoganAge Related Healthcare, Tallaght University Hospital, Dublin, Ireland;
,
Eileen KelleherHaematology, Bon Secours Hospital, Cork, Ireland;
,
Philip T. MurphyHaematology, Beaumont Hospital, Dublin, Ireland;
,
John QuinnHaematology, Beaumont Hospital, Dublin, Ireland;
,
Ronan DesmondHaematology, Tallaght University Hospital, Dublin, Ireland;
,
John McHughHaematology, Tallaght University Hospital, Dublin, Ireland;
,
Melanie StricklandHaematology, Tallaght University Hospital, Dublin, Ireland;
,
Elizabeth O'ConnellHaematology, Tallaght University Hospital, Dublin, Ireland;
,
Mary CahillHaematology, Cork University Hospital and University College Cork, Cork, Ireland;
,
Su W. MaungHaematology, Mater Misericordiae University Hospital, Dublin, Ireland; ORCID Iconhttp://orcid.org/0000-0002-2679-8896
ORCID Icon,
Clodagh KeohaneHaematology, Mercy University Hospital Cork, Cork, Ireland
,
Desmond O'NeillAge Related Healthcare, Tallaght University Hospital, Dublin, Ireland;
,
Dan RyanAge Related Healthcare, Tallaght University Hospital, Dublin, Ireland;
,
Vitaliy MykytivHaematology, Cork University Hospital and University College Cork, Cork, Ireland;
&
Helen EnrightHaematology, Tallaght University Hospital, Dublin, Ireland;
show all
Pages 1324-1327 | Received 18 Sep 2018, Accepted 10 Oct 2018, Published online: 11 Jan 2019

References

  • Swerdlow SH, Campo E, Harris N, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2008.
  • Greenberg PL, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012; 120:2454–2465.
  • Killick SB, Carter C, Culligan D, et al. Guidelines for the diagnosis and management of adult myelodysplastic syndromes. Br J Haematol. 2014;164:503–525.
  • Silverman LR, Demakos EP, Peterson BL, et al. Randomised, controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia Group B. J Clin Oncol. 2002;20:2429–2440.
  • Ma X. Epidemiology of myelodysplastic syndromes. Am J Med. 2012;125:S2–S5.
  • Stauder R. The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes patients. Ann Hematol. 2012;91:1333–1343.
  • Sperling AS, Gibson CJ, Ebert EL. The genetics of myelodysplastic syndrome: from clonal hematopoiesis to secondary leukemia. Nat Rev Cancer. 2017;17:5–19.
  • Guralnik JM, Eisenstaedt RS, Ferrucci L, et al. Prevalence of anemia in persons 65 years and older in the United States: evidence for a high rate of unexplained anemia. Blood 2004;104:2263–2268.
  • Ma X, Steensma DP, Scott BL, et al. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States. BMJ Open. 2018;8:e019955.
  • Lobrezia FR Jr, Cannon AC, Cannon AJ, et al. Insights on practice variations in the management of lymphoma and leukemia. Leuk Lymphoma 2014;55:2449–2456.
  • van Spronsen MF, Ossenkoppele GJ, Holman R, et al. Improved risk stratification by the integration of the revised international prognostic scoring system with the myelodysplastic syndromes comorbidity index. Eur J Cancer. 2014;50:3198–3205.
  • Hamaker MA, Prins MC, Stauder R. The relevance of a geriatric assessment for elderly patients with a haematological malignancy – a systematic review. Leuk Res. 2014;38:275–283.
  • Seymour JF, Fenaux P, Silverman LR, et al. Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes. Crit Rev Oncol Hematol. 2010;76:218–227.
  • Xicoy B, Jimenez MJ, Garcia O, et al. Results of treatment with azacitidine in patients aged ≥75 years included in the Spanish registry of myelodysplastic syndromes. Leuk Lymphoma. 2014;55:1300–1303.
  • Public Health England. Life expectancy: recent trends in older ages. A summary of recent trends in life expectancy among those aged 65 and over in England. PHE Publications Feb 2016, Gateway number 2015661.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.